An initiative deploying physIQ’s http://www.physiq.com platform to be used to collect and analyze wearable sensor data to better understand the pathophysiology of COVID-19 has been launched by the Department of Defense https://dod.defense.gov and the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) https://www.hjf.org.
The initiative is also being conducted with the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) https://www.jpeocbrnd.osd.mil.
The physIQ’s continuous monitoring platform with sophisticated personalized algorithms will be used to evaluate physiologic signals to predict disease progression and early indication of infection, and then potentially evaluate novel treatments for COVID-19.
This DOD initiative with funding support from the Defense Health Agency https://health.mil, will assess the role of home-based continuous biosensor data.
Confirmed COVID-19 positive individuals and patients at high risk of exposure will wear a clinical grade biosensor to continuously stream data to physIQ’s platform where advanced FDA cleared AI-based analytics will process the raw vital sign data.
In another research effort, the Southwest Research Institute (SwRI) https://swri.org will use Department of Defense (DOD) supercomputers to virtually screen millions of drug compounds to search for and test possible treatment options for COVID-19.
To perform the research, HJF awarded SwRI a $1.9 million one year contract to identify potential COVID-19 treatments. SwRI is working with DOD’s High Performance Computing Modernization Program to rapidly screen for potential drug compounds by using SwRI’s 3D drug screening software tool Rhodium™. Rhodium helps scientists rapidly predict how protein structures in infectious diseases will bind with drug compounds to find viable candidates for development into therapies.